Sitravatinib - Mirati Therapeutics
Alternative Names: IND-155305; MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-TherapeuticsLatest Information Update: 20 Jul 2024
At a glance
- Originator MethylGene
- Developer BeiGene; Cancer Research UK; Columbia University; Fudan University; Mirati Therapeutics; University Health Network; University of Birmingham
- Class Amides; Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Proto-oncogene protein c-ret inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE-2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
- Phase II/III Solid tumours
- Phase II Biliary cancer; Cholangiocarcinoma; Liposarcoma; Liver cancer; Oesophageal cancer; Soft tissue sarcoma; Squamous cell cancer; Urogenital cancer; Uveal melanoma
- Phase I/II Gastric cancer
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from phase II trial in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Renal cell carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 M.D. Anderson Cancer Center discontinues a phase II trial in Renal cell carcinoma in USA due to discontinuation of sitravatinib development by the sponsor (NCT04904302)